Top videos
An antisperm antibody test looks for special proteins (antibodies) that fight against a man's sperm in blood, vaginal fluids, or semen. The test uses a sample of sperm and adds a substance that binds only to affected sperm. Semen can cause an immune system response in either the man's or woman's body. The antibodies can damage or kill sperm. If a high number of sperm antibodies come into contact with a man's sperm, it may be hard for the sperm to fertilize an egg. The couple has a hard time becoming pregnant. This is called immunologic infertility.
Syringomyelia is a cystic cavitation of the spinal cord associated with Chiari I malformation (70%) or basilar invagination (10%) or tumor. It may be a post-traumatic condition. There are 2 main forms: communicating with the central canal or subarachnoid spaces (Chiari I malformation); non communicating (trauma, tumors).
Haemorrhoids is one of the most common problems seen in surgical OPD. Open haemorrhoidectomy has remained the gold standard for a long time with a high post-operative morbidity. The quest for a better understanding of the pathology of haemorrhoids resulted in the evolvement of stapler haemorrhoidopexy. Our aim is to study the efficacy of stapler haemorrhoidopexy with regards to role of immediate post-operative morbidity. A prospective study of 50 patients (n = 50) with the second- and third-degree symptomatic haemorrhoids was done. The mean age of the patients was 44.1 years. Fourteen patients had co-morbid conditions. The average duration of the operation was 29 min. Patients with the second-degree haemorrhoids had higher rate of complication. The complication rate was 32%. Three patients had urinary retention. Two patients had minor bleeding, and one patient experienced transient discharge. The mean analgesic requirement was 2.4 tramadol, 50 mg injections. Ten patients had significant post-operative pain. Average length of hospital stay was 2.7 days. There were no symptomatic recurrences till date.
Reduction techniques can vary in terms of required force, time, equipment, and staff. [7] No single reduction method is successful in every instance; therefore, the clinician should be familiar with several reduction techniques. Techniques commonly used to reduce anterior shoulder dislocations include the following [35, 36, 37, 38, 39] : Stimson maneuver Scapular manipulation External rotation Milch technique Spaso technique Traction-countertraction
hemothorax is most often defined as rapid accumulation of ≥ 1000 mL of blood. Shock is common. Patients with large hemorrhage volume are often dyspneic and have decreased breath sounds and dullness to percussion (often difficult to appreciate during initial evaluation of patients with multiple injuries).
Vascular dementia is a general term describing problems with reasoning, planning, judgment, memory and other thought processes caused by brain damage from impaired blood flow to your brain. You can develop vascular dementia after a stroke blocks an artery in your brain, but strokes don't always cause vascular dementia. Whether a stroke affects your thinking and reasoning depends on your stroke's severity and location. Vascular dementia also can result from other conditions that damage blood vessels and reduce circulation, depriving your brain of vital oxygen and nutrients
Antiphospholipid (AN-te-fos-fo-LIP-id) syndrome occurs when your immune system attacks some of the normal proteins in your blood. It can cause blood clots in your arteries or veins. And it can cause pregnancy complications, such as miscarriage and stillbirth. Blood clots in your leg veins cause a condition known as deep vein thrombosis (DVT). Damage from blood clots in your organs, such as your kidneys, lungs or brain, depends on the extent and location of the clot. For instance, a clot in your brain can cause a stroke. There's no cure for antiphospholipid syndrome, but medications can reduce your risk of blood clots.
The pathobiology of MM is complex and the root underlying cause of myeloma is the multistep genetic changes in the postgerminal center B cell. In addition, the bone marrow microenvironment plays a crucial role.[2] The interaction between myeloma cells and the microenvironment is mediated through adhesive interactions via cell-surface receptors, paracrine loops involving several cytokines, such as IL-6, VEGF and IL-10, and suppression of cell-mediated immunity.[2–4] IMiDs modulate many of these interactions leading to decreased myeloma cell growth and survival. Thalidomide was the first IMiD introduced to treat MM. It was initially synthesized in Germany in the late 1950s to treat insomnia and morning sickness. It was withdrawn from the market in 1961 because of its teratogenic effects. Its immunomodulatory properties were realized when it was observed to improve erythema nodosum leprosum, a painful immunologic reaction of leprosy, leading to its approval by the FDA in 1998 with tight prescribing and marketing regulations. Subsequent research showed the diverse mechanism of action of thalidomide including its immunomodulatory effect by inhibition of de novo IgM antibody synthesis,[5] modulation of the T-cell subset by increasing the T-helper cells, inhibitory effects on the TNF-α and antiangiogenic activity leading to its use in MM. Significantly higher response rates in combination with dexamethasone led to its approval in the treatment of newly diagnosed MM in 2006. Lenalidomide, a second-generation IMiD, was developed from the structural backbone of the thalidomide molecule by the addition of an amino group (NH2-) at position 4 of the phthaloyl ring and removal of the carbonyl group (C = O) of the 4-amino-substituted phthaloyl ring (Table 1).[6] In addition to immunomodulatory effects, other mechanisms of action have been described such as direct cytotoxicity via induction of apoptosis, inhibition of cell adhesion molecules and inhibition of growth signals that promote bone marrow angiogenesis